Coherus BioSciences Inc
NASDAQ:CHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Coherus BioSciences Inc
NASDAQ:CHRS
|
US |
|
C
|
Camtek Ltd
TASE:CAMT
|
IL |
|
R
|
Rushil Decor Ltd
BSE:533470
|
IN |
|
F
|
Fortrea Holdings Inc
NASDAQ:FTRE
|
US |
|
I
|
Intercontinental Exchange Inc
SWB:IC2
|
US |
|
I
|
Imax Corp
XBER:IMA
|
CA |
|
L
|
Lexicon Pharmaceuticals Inc
F:LX31
|
US |
|
Eastern Bankshares Inc
F:EB0
|
US |
|
Bukit Sembawang Estates Ltd
SGX:B61
|
SG |
|
D
|
Deutsche Boerse AG
XMUN:DB1
|
DE |
|
V
|
VGI PCL
SET:VGI
|
TH |
|
C
|
Capgemini SE
OTC:CAPMF
|
FR |
|
8x8 Inc
LSE:0IFS
|
US |
|
A
|
Allied Gold Corp
TSX:AAUC
|
CA |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
US |
|
S
|
Sundial Growers Inc
F:14K
|
CA |
|
F
|
Farmacosmo SpA
MIL:COSMO
|
IT |
|
Vusiongroup SA
PAR:VU
|
FR |
Wall St Price Targets
CHRS Price Targets Summary
Coherus BioSciences Inc
According to Wall Street analysts, the average 1-year price target for
CHRS is 7.4 USD with a low forecast of 4.04 USD and a high forecast of 12.6 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CHRS's stock price target?
Price Target
7.4
USD
According to Wall Street analysts, the average 1-year price target for
CHRS is 7.4 USD with a low forecast of 4.04 USD and a high forecast of 12.6 USD.
What is the Revenue forecast for Coherus BioSciences Inc?
Projected CAGR
46%
Over the last 12 years, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 8 years is 46%.
What is the Gross Profit forecast for Coherus BioSciences Inc?
Projected CAGR
50%
The compound annual growth rate for Gross Profit over the next 7 years is 50%.